A clinical trial to study the effects of Bevacizumab injection (Hetero) against Reference Medicinal Product (Reference product, Roche) in patients suffering from metastatic colorectal cancer

Intervention1: Bevacizumab (Hetero): Bevacizumab is given at the dose of 7.5mg/kg, every 3 weeks for up to 08 cycles along with standard chemotherapy. Bevacizumab is given at the dose of 5mg/kg, every 2 weeks for up to 12 cycles along with standard chemotherapy. Control Intervention1: Bevacizumab (Roche): Bevacizumab is given at the dose of 7.5mg/kg, every 3 weeks for up to 08 cycles along with standard chemotherapy. Bevacizumab is given at the dose of 5mg/kg, every 2 weeks for up to 12 cycles along with standard chemotherapy. Primary outcome(s): Disease control rate as per RECIST 1.1 criteriaTimepoint: At baseline and end of treatment cycles Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Permuted block randomization, fixed Method of allocation concealment:Centralized Blinding and masking:Open Label